Publications by authors named "Gloria Boni"
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial.
Karolina Akinosoglou Antigone Kotsaki Ioanna-Maria Gounaridi Eirini Christaki Simeon Metallidis Gloria Boni
EClinicalMedicine
February 2023
Background: The SAVE-MORE trial demonstrated that anakinra treatment in COVID-19 pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or more was associated with 0.36 odds for a worse outcome compared to placebo when expressed by the WHO-Clinical Progression Scale (CPS) at day 28. Herein, we report the results of subgroup analyses and long-term outcomes.
View Article and Find Full Text PDFArticle Synopsis
- The IASP ICD-11 defines chronic primary pain (CPP) and notes increasing interest in cannabinoids as a treatment, though evidence for their efficacy in CPP is limited.
- This systematic review aims to analyze the effectiveness and safety of cannabinoids for managing CPP by reviewing randomized controlled trials and other studies.
- The review included eight studies from 3007 records, focusing on outcomes like pain reduction, quality of life, and various mental health aspects, along with assessing safety and potential biases.